EPIX
ESSA Pharma Inc - Terminates Masofaniten Clinical Trials, Exploring Strategic Options
时间：2025-02-11 20:05:52 市场： 美股 综合
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024
时间：2024-12-17 20:00:05 市场： 美股 综合
Tang Capital Management, Llc Reports 9.7% Stake in ESSA Pharma as of Nov 1- SEC Filing
时间：2024-11-09 05:58:26 市场： 美股 综合
ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
时间：2024-11-01 08:57:49 市场： 美股 综合
ESSA Pharma - Combination of Masofaniten Plus Enzalutamide Continues to Be Well Tolerated With Durable Reductions in Psa in Patients With Mcrpc
时间：2024-09-14 05:20:33 市场： 美股 综合
ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 Esmo Congress
时间：2024-09-14 05:20:33 市场： 美股 综合